Search companies

Live

PERCHERON THERAPEUTICS LIMITED (ASX: PER)

Health care · News and insights

Price unavailable

Latest PER announcements

Announcement Insights

Percheron Advances HMBD-002 Leukaemia Study as Capital Raising Drives Large Option Issue

Percheron’s HMBD-002 programme moved closer to clinical testing after the FDA cleared Vanderbilt Health’s investigator-sponsored study for up to 20 patients with relapsed or refractory acute myeloid leukaemia and related disease. Alongside that development, the company completed a $2.3 million capital raising and issued 575 million options tied to earlier rights issues and placements, applying for their ASX quotation; the issue includes 50 million options for joint lead managers as fees.

Updated 06 Nov 2026, 12:36 PM Sydney time
Share
SourcesNotification regarding unquoted securities - PERApplication for quotation of securities - PERTop 20 Optionholders and Distribution ListChange of Director's Interest NoticeProspectus - Placement options and JLM optionsUpdate - Proposed issue of securities - PERUpdate - Proposed issue of securities - PERUpdate - Proposed issue of securities - PERFDA Clearance for Vanderbilt Health Clinical Trial in AMLListing Rule waiver to allow quotation of PERAQ options
Comments

Percheron Issues 575 Million Options, Including 10 Million to Director Michael Baker

2026-11-06 · Health care

PER: $0.004 +16.67% · MC: $6M

Percheron Therapeutics issued 575 million options exercisable at one cent by April 2028, covering options linked to earlier rights issues and placements, and has applied for their ASX quotation. Director Michael Baker acquired 10 million of the free-attaching options through his participation in the September placement; the company also issued 50 million options to joint lead managers as fees.

Updated 2026-11-06 12:22
Share
SourcesNotification regarding unquoted securities - PERApplication for quotation of securities - PERTop 20 Optionholders and Distribution ListChange of Director's Interest Notice
Comments

Percheron Seeks Quotation For Up To 280 Million Options After Recent Capital Raise

2026-11-04 · Health care

PER: $0.003 +0.00% · MC: $6M

Percheron Therapeutics has lodged a prospectus offering up to 280 million options—230 million to placement participants and 50 million to joint lead managers—and is seeking ASX quotation for them. The options relate to the recent placement and manager fees; the prospectus follows an earlier announcement that the company had completed a $2.3 million capital raising.

Updated 2026-11-04 08:57
Share
SourcesProspectus - Placement options and JLM optionsUpdate - Proposed issue of securities - PERUpdate - Proposed issue of securities - PERUpdate - Proposed issue of securities - PER
Comments

Percheron Wins FDA Clearance for HMBD-002 Blood Cancer Trial

2026-11-02 · Health care

PER: $0.003 +0.00% · MC: $6M

The FDA has cleared Vanderbilt Health to proceed with an investigator-sponsored study of Percheron Therapeutics’ HMBD-002 alongside established treatments in patients with relapsed or refractory acute myeloid leukaemia or related disease. The study is planned to enrol up to 20 patients; Percheron will supply the drug and support the trial, with access to the resulting data. This advances the study beyond the earlier announcement of Vanderbilt’s role, but does not establish clinical benefit.

Updated 2026-11-02 10:25
Share
SourcesFDA Clearance for Vanderbilt Health Clinical Trial in AML
Comments

Percheron Wins ASX Waiver to Seek Quotation for Existing Options

2026-10-30 · Health care

PER: $0.003 +0.00% · MC: $6M

Percheron Therapeutics has secured an ASX waiver allowing it to amend the terms of existing options so it can apply to have them quoted alongside options linked to its recent capital raising. The company intends to lodge a prospectus for the placement and broker options, with quotation of the option classes proposed to begin in November.

Updated 2026-10-30 11:44
Share
SourcesListing Rule waiver to allow quotation of PERAQ options
Comments